Review of registered clinical trials for the treatment of COVID‐19

DOI Web Site Web Site 被引用文献1件
  • Fatemeh Babaei
    Department of Clinical Biochemistry, School of Medicine, Student Research Committee Shahid Beheshti University of Medical Sciences Tehran Iran
  • Mohammadreza Mirzababaei
    Department of Clinical Biochemistry, School of Medicine Kermanshah University of Medical Sciences Kermanshah Iran
  • Marjan Nassiri‐Asl
    Department of Pharmacology and Neurobiology Research Center Shahid Beheshti University of Medical Sciences Tehran Iran
  • Hossein Hosseinzadeh
    Department of Pharmacodynamics and Toxicology, School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran

抄録

<jats:title>Abstract</jats:title><jats:p>Coronavirus disease 2019 (COVID‐19) is a viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The disease was first reported in December 2019 in Wuhan, China, but now more than 200 countries have been affected and the coronavirus pandemic is still ongoing. The severity of COVID‐19 symptoms can range from mild to severe. FDA approved remdesivir as a treatment of COVID‐19 so far. Various clinical trials are underway to find an effective method to treat patients with COVID‐19. This review aimed at summarizing 219 registered clinical trials in <jats:italic>the ClinicalTrials.gov</jats:italic> database with possible mechanisms, and novel findings of them, and other recent publications related to COVID‐19. According to our analyses, various treatment approaches and drugs are being investigated to find an effective drug to cure COVID‐19 and among all strategies, three important mechanisms are suggested to be important against COVID‐19 including antiviral, anti‐inflammatory, and immunomodulatory properties. Our review can help future studies get on the way to finding an effective drug for COVID‐19 treatment by providing ideas for similar researches.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ